Boehringer Ingelheim and Peking University (PKU), has strategic partnership for jointly advancing early science innovation across a range of areas of high medical need.
Nature of the partnership: Collaboration and Development Model
The partnership aims to strengthen Boehringer Ingelheim’s portfolio of early and unique pipeline projects with breakthrough potential.
Research teams at PKU will work closely with their counterparts at Boehringer Ingelheim to leverage the company’s expertise in pharmaceutical research and development with their novel approaches and insights to identify novel targets and medicines within and beyond the company’s key therapeutic areas. These include cancer, cancer immunology and immune modulation, respiratory, cardiometabolic and central nervous system diseases.